Myocardial enterovirus infection with left ventricular dysfunction: a benign disease compared with idiopathic dilated cardiomyopathy

Department of Internal Medicine, University of Gottingen, Germany.

OBJECTIVES. Endomyocardial biopsy samples from patients with idiopathic dilated cardiomyopathy were screened for the presence of enterovirus genome. Patients with enterovirus-positive samples were further studied with regard to disease course, histologic variables and response to interferon-alpha treatment. BACKGROUND. Studies of patients with idiopathic dilated cardiomyopathy have reported widely divergent clinical outcomes, suggesting that there is no unique underlying pathogenetic mechanism. METHODS. Five left ventricular endomyocardial biopsy samples were screened for the presence of the enterovirus genome by an established in situ hybridization technique in combination with a histologic, histomorphometric and immunohistologic workup. The course of the disease was then prospectively followed for up to 50 months. Virus-positive patients whose condition deteriorated were treated with interferon-alpha. RESULTS. Of 77 patients, 20 (26%) had enterovirus-positive and 57 (74%) enterovirus-negative biopsy samples. During a mean follow-up period of 25.8 +/- 13.7 months, 1 patient in the enterovirus-positive group and 11 in the enterovirus-negative group died. Four patients in the enterovirus-negative group underwent heart transplantation (p < 0.05). The surviving 19 enterovirus-positive patients had a decrease in mean left ventricular end-diastolic diameter from 66 to 61 mm (p < 0.05) and a mean increase in left ventricular ejection fraction from 0.35 to 0.43 (p < 0.05). In contrast, enterovirus-negative patients had no significant change in end-diastolic diameter or left ventricular ejection fraction. Four patients in the enterovirus-positive group whose condition deteriorated were treated with a 6-month course of subcutaneous interferon-alpha (3 x 10(6) U every second day). This treatment induced hemodynamic improvement in all four patients and eliminated the persistent enteroviral infection in two. CONCLUSIONS. Enterovirus-positive patients have a better heart transplantation-free survival rate and hemodynamic course, with fewer histologic changes, than do enterovirus-negative patients. In addition, enterovirus-positive patients respond favorably to interferon-alpha treatment. These observations indicate that myocardial enteroviral infection with associated left ventricular dysfunction is a distinct disease entity with a benign course.

This article has been cited by other articles:

				N. F. Murphy, C. O'Loughlin, M. Ledwidge, D. McCaffrey, and K. McDonald Improvement but no cure of left ventricular systolic dysfunction in treated heart failure patients Eur J Heart Fail, December 1, 2007; 9(12): 1196 - 1204. [Abstract] [Full Text] [PDF]

				A. L.P. Caforio, F. Calabrese, A. Angelini, F. Tona, A. Vinci, S. Bottaro, A. Ramondo, E. Carturan, S. Iliceto, G. Thiene, et al. A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis Eur. Heart J., June 1, 2007; 28(11): 1326 - 1333. [Abstract] [Full Text] [PDF]

				J. W. Magnani and G. W. Dec Myocarditis: Current Trends in Diagnosis and Treatment Circulation, February 14, 2006; 113(6): 876 - 890. [Full Text] [PDF]

				U. Kuhl, M. Pauschinger, P. L. Schwimmbeck, B. Seeberg, C. Lober, M. Noutsias, W. Poller, and H.-P. Schultheiss Interferon-{beta} Treatment Eliminates Cardiotropic Viruses and Improves Left Ventricular Function in Patients With Myocardial Persistence of Viral Genomes and Left Ventricular Dysfunction Circulation, June 10, 2003; 107(22): 2793 - 2798. [Abstract] [Full Text] [PDF]

				J R L. HAMILTON and A. HASAN Cardiopulmonary transplantation in children: a reason for optimism? Heart, December 1, 2001; 86(6): 607 - 608. [Full Text] [PDF]

				A. Staudt, F. Schaper, V. Stangl, A. Plagemann, M. Bohm, K. Merkel, G. Wallukat, K. D. Wernecke, K. Stangl, G. Baumann, et al. Immunohistological Changes in Dilated Cardiomyopathy Induced by Immunoadsorption Therapy and Subsequent Immunoglobulin Substitution Circulation, June 5, 2001; 103(22): 2681 - 2686. [Abstract] [Full Text] [PDF]

				A D'Ambrosio, G Patti, A Manzoli, G Sinagra, A Di Lenarda, F Silvestri, and G Di Sciascio The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: a review Heart, May 1, 2001; 85(5): 499 - 504. [Full Text]

				M T Kearney, J M Cotton, P J Richardson, and A M Shah Viral myocarditis and dilated cardiomyopathy: mechanisms, manifestations, and management Postgrad. Med. J., January 1, 2001; 77(903): 4 - 10. [Abstract] [Full Text]

				A. Heim, S. Zeuke, S. Weiss, W. Ruschewski, and I. M. Grumbach Transient Induction of Cytokine Production in Human Myocardial Fibroblasts by Coxsackievirus B3 Circ. Res., April 14, 2000; 86(7): 753 - 759. [Abstract] [Full Text] [PDF]

				M. Pauschinger, A. Doerner, U. Kuehl, P. L. Schwimmbeck, W. Poller, R. Kandolf, and H.-P. Schultheiss Enteroviral RNA Replication in the Myocardium of Patients With Left Ventricular Dysfunction and Clinically Suspected Myocarditis Circulation, February 23, 1999; 99(7): 889 - 895. [Abstract] [Full Text] [PDF]

				A. Arola, J. Tuominen, O. Ruuskanen, and E. Jokinen Idiopathic Dilated Cardiomyopathy in Children: Prognostic Indicators and Outcome Pediatrics, March 1, 1998; 101(3): 369 - 376. [Abstract] [Full Text] [PDF]

				H. R. Figulla, F. Gietzen, U. Zeymer, M. Raiber, J. Hegselmann, R. Soballa, and R. Hilgers Diltiazem Improves Cardiac Function and Exercise Capacity in Patients With Idiopathic Dilated Cardiomyopathy: Results of the Diltiazem in Dilated Cardiomyopathy Trial Circulation, August 1, 1996; 94(3): 346 - 352. [Abstract] [Full Text]